Jilin Aodong subsidiary gets revised drug standard approval

Jilin Aodong Pharmaceutical announced its subsidiary Jilin Aodong Taonan Pharmaceutical received revised national drug standards for "Calf Spleen Extractive Injection" from China's National Medical Products Administration.

The updated standard becomes effective January 3, 2026, and covers quality requirements including identification, molecular weight substances, amino acids, and biological activity. The drug is used for enhancing immunity and treating conditions including anemia and tumors.